Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 8Other hematologic neoplasm 5Lymphoid 4Classical hematology 3Thoracic 2Head & Neck 2Gastrointestinal 2Sarcoma 1Endocrine 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 2310Glioblastoma 2014Glioma 1399Central Nervous System Neoplasms 692Astrocytoma 667Neuroblastoma 647Gliosarcoma 480Neoplasms 405Oligodendroglioma 404Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 255Meningioma 229Recurrence 224Sarcoma 214Melanoma 206Neoplasm Metastasis 202Lung Neoplasms 199Ependymoma 199Neurofibromatosis 1 169Lymphoma 161Meningeal Carcinomatosis 138Osteosarcoma 134Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 106

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × CNS × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡